A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway

References

• Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344(14):1058–1066.
   PubMed Web of Science ®Google Scholar
• Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med. 2008;12(4):1074–1084.
   PubMed Web of Science ®Google Scholar
• Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol. 2009;104:115–149.
   PubMed Web of Science ®Google Scholar
• Merrill SA, Brodsky RA. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematol Am Soc Hematol Educ Program. 2018;2018(1):371–376.
   PubMedGoogle Scholar
• Richani K, Soto E, Romero R, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17(4):239–245.
   PubMed Web of Science ®Google Scholar
• Kim MY, Guerra MM, Kaplowitz E, et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018;77(4):549–555.
   PubMed Web of Science ®Google Scholar
• Maga TK, Nishimura CJ, Weaver AE, et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010;31(6):E1445–60.
   PubMed Web of Science ®Google Scholar
• Medof ME, Lublin DM, Holers VM, et al. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci USA. 1987;84(7):2007–2011.
   PubMed Web of Science ®Google Scholar
• Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol. 1991;9(1):431–455.
   PubMedGoogle Scholar
• Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990;144(9):3478–3483.
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Dragon-Durey M-A, Blouin J, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet. 2004;41(6):e84–e84.
   PubMed Web of Science ®Google Scholar
• Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol. 1989;46:183–219.
   PubMed Web of Science ®Google Scholar
• Pangburn MK. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol. 2002;169(9):4702–4706.
   PubMed Web of Science ®Google Scholar
• Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol. 1996;61:201–283.
   PubMed Web of Science ®Google Scholar
• Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2):379–387.
   PubMed Web of Science ®Google Scholar
• Francis NJ, McNicholas B, Awan A, et al. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood. 2012;119(2):591–601.
   PubMed Web of Science ®Google Scholar
• Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol. 2015;67(1):56–70.
   PubMed Web of Science ®Google Scholar
• Holmes CH, Simpson KL, Okada H, et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol. 1992;22(6):1579–1585.
   PubMed Web of Science ®Google Scholar
• Tedesco F, Narchi G, Radillo O, et al. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol. 1993;151(3):1562–1570.
   PubMed Web of Science ®Google Scholar
• Nishikori K, Noma J, Hirakawa S, et al. The change of membrane complement regulatory protein in chorion of early pregnancy. Clin Immunol Immunopathol. 1993;69(2):167–174.
   PubMedGoogle Scholar
• Agostinis C, Bulla R, Tripodo C, et al. An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. JI. 2010;185(7):4420–4429.
   Google Scholar
• Agostinis C, Bossi F, Masat E, et al. MBL interferes with endovascular trophoblast invasion in pre-eclampsia. Clin Dev Immunol. 2012;2012:1–7.
   Google Scholar
• van de Geijn FE, Roos A, de Man YA, et al. Mannose-binding lectin levels during pregnancy: a longitudinal study. Hum Reprod. 2007;22(2):362–371.
   PubMed Web of Science ®Google Scholar
• Derzsy Z, Prohászka Z, Rigó J Jr, et al. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. 2010;47(7-8):1500–1506.
   PubMed Web of Science ®Google Scholar
• Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3(1):17028.
   PubMedGoogle Scholar
• Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811.
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–1264.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847.
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–737.
   PubMed Web of Science ®Google Scholar
• Ray JG, Burows RF, Ginsberg JS, et al. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Pathophysiol Haemos Thromb. 2000;30(3):103–117.
   Google Scholar
• Bais J, Pel M, von Dem Borne A, et al. Pregnancy and paroxysmal nocturnal hemoglobinuria. Eur J Obstet Gynecol Reprod Biol. 1994;53(3):211–214.
   PubMed Web of Science ®Google Scholar
• Fieni S, Bonfanti L, Gramellini D, et al. Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review. Obstet Gynecol Surv. 2006;61(9):593–601.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–1039.
   PubMed Web of Science ®Google Scholar
• Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6(1):60.
   PubMedGoogle Scholar
• Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67(1):31–42.
   PubMed Web of Science ®Google Scholar
• Baines AC, Brodsky RA. Complementopathies. Blood Rev. 2017;31(4):213–223.
   PubMed Web of Science ®Google Scholar
• Noris M, Bresin E, Mele C, et al. Genetic atypical hemolytic-uremic syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al. editors. GeneReviews^®. Seattle (WA): University of Washington, Seattle; 2007.
   Google Scholar
• Esparza-Gordillo J, de Jorge EG, Garrido CA, et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol. 2006;43(11):1769–1775.
   PubMed Web of Science ®Google Scholar
• Sridharan M, Go RS, Willrich M. Atypical hemolytic uremic syndrome: review of clinical presentation, diagnosis and management. J Immunol Methods. 2018;461:15–22.
   PubMed Web of Science ®Google Scholar
• Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. CJASN. 2010;5(10):1844–1859.
   PubMed Web of Science ®Google Scholar
• Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. Semin Thromb Hemost. 2016;42(07):774–779.
   PubMedGoogle Scholar
• Gavriilaki E, Yuan X, Ye Z, et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood. 2015;125(23):3637–3646.
   PubMed Web of Science ®Google Scholar
• Merrill SA, Brittingham ZD, Yuan X, et al. Eculizumab cessation in atypical hemolytic uremic syndrome. Blood. 2017;130(3):368–372.
   PubMed Web of Science ®Google Scholar
• Ardissino G, Tel F, Sgarbanti M, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018;33(3):457–461.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. JASN. 2010;21(5):859–867.
   Web of Science ®Google Scholar
• Saad AF, Roman J, Wyble A, et al. Pregnancy-associated atypical hemolytic-uremic syndrome. AJP Rep. 2016;06(01):e125–8.
   Google Scholar
• Gaggl M, Aigner C, Csuka D, et al. Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29(3):1020–1029.
   PubMed Web of Science ®Google Scholar
• Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93(2):450–459.
   PubMed Web of Science ®Google Scholar
• Demir E, Yazici H, Ozluk Y, et al. Pregnant woman with atypical hemolytic uremic syndrome delivered a healthy newborn under eculizumab treatment. Case Rep Nephrol Dial. 2016;6(3):143–148.
   PubMed Web of Science ®Google Scholar
• Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508–530.
   PubMed Web of Science ®Google Scholar
• Aloizos S, Seretis C, Liakos N, et al. HELLP syndrome: understanding and management of a pregnancy-specific disease. J Obstet Gynaecol. 2013;33(4):331–337.
   PubMedGoogle Scholar
• Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169(4):1000–1006.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–1131.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006;195(4):914–934.
   PubMed Web of Science ®Google Scholar
• Lu F, Longo M, Tamayo E, et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol. 2007;196(4):396.e1–396.e7. 7; discussion.
   PubMed Web of Science ®Google Scholar
• Huppertz B. Biology of preeclampsia: combined actions of angiogenic factors, their receptors and placental proteins. Biochim Biophys Acta Mol Basis Dis. 2020;1866(2):165349.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–683.
   PubMed Web of Science ®Google Scholar
• McGinnis R, Steinthorsdottir V, Williams NO, et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. Nat Genet. 2017;49(8):1255–1260.
   PubMed Web of Science ®Google Scholar
• Gray KJ, Saxena R, Karumanchi SA. Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis. Am J Obstet Gynecol. 2018;218(2):211–218.
   PubMed Web of Science ®Google Scholar
• Vaught AJ, Braunstein EM, Jasem J, et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018;3(6):99128.
   PubMed Web of Science ®Google Scholar
• Fang CJ, Richards A, Liszewski MK, et al. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol. 2008;143(3):336–348.
   PubMed Web of Science ®Google Scholar
• Vaught AJ, Gavriilaki E, Hueppchen N, et al. Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. Exp Hematol. 2016;44(5):390–398.
   PubMed Web of Science ®Google Scholar
• Crovetto F, Borsa N, Acaia B, et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med. 2012;25(11):2322–2325.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Jablonski M, Lepercq J, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008;112(12):4542–4545.
   PubMed Web of Science ®Google Scholar
• Burwick RM, Fichorova RN, Dawood HY, et al. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62(6):1040–1045.
   PubMed Web of Science ®Google Scholar
• Burwick RM, Velásquez JA, Valencia CM, et al. Terminal complement activation in preeclampsia. Obstet Gynecol. 2018;132:1477–1485.
   PubMed Web of Science ®Google Scholar
• Lynch AM, Gibbs RS, Murphy JR, et al. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. 2011;117:75–83.
   PubMed Web of Science ®Google Scholar
• Lynch AM, Murphy JR, Byers T, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. 2008;198(4):385.e1–385.e9.
   Web of Science ®Google Scholar
• Hoffman MC, Rumer KK, Kramer A, Lynch AM, et al. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol. 2014;71(1):55–60.
   PubMed Web of Science ®Google Scholar
• Koseoglu M, Hur A, Atay A, et al. Effects of hemolysis interferences on routine biochemistry parameters. Biochem Med. 2011;21:79–85.
   PubMed Web of Science ®Google Scholar
• Gedik E, Yücel N, Sahin T, et al. Hemolysis, elevated liver enzymes, and low platelet syndrome: outcomes for patients admitted to intensive care at a tertiary referral hospital. Hypertens Pregnancy. 2017;36(1):21–29.
   PubMed Web of Science ®Google Scholar
• Ferreira E, Oliveira N, Marques M, et al. Subcapsular liver hematoma as a complication of an atypical hemolytic uremic syndrome. Nefrologia. 2015;35(3):337–339.
   PubMed Web of Science ®Google Scholar
• Mihu D, Costin N, Mihu CM, et al. HELLP syndrome – a multisystemic disorder. J Gastrointestin Liver Dis. 2007;16(4):419–424.
   PubMed Web of Science ®Google Scholar
• Manuck TA, Rice MM, Bailit JL, et al. Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort. Am J Obstet Gynecol. 2016;215(1):103.e1–103.e14.
   PubMed Web of Science ®Google Scholar